{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-278946","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2023-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.530501+00:00","generated_at":"2026-06-08T01:20:59.509442+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Royalty Pharma files prospectus for 383,000 shares under equity incentive plan","bullets":["Prospectus supplement covers up to 383,000 Class A ordinary shares.","Shares to be awarded to employees and consultants of RP Management LLC.","Awards granted under the RP Management Equity Incentive Plan.","Legal opinion from Davis Polk & Wardwell filed as Exhibit 5.1."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-278946","json":"https://secwatch.observer/filing/0001193125-23-278946.json","markdown":"https://secwatch.observer/filing/0001193125-23-278946.md","text":"https://secwatch.observer/filing/0001193125-23-278946.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312523278946/0001193125-23-278946-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312523278946/d576980d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T01:20:59.509442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}